Global burden of hepatitis C: considerations for healthcare providers in the United States.

Authors: Averhoff FM,Glass N,Holtzman D,
Address: Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30333, USA. fma0@cdc.gov
Journal: Clin Infect Dis.


Publication: 2012 Jul;55 Suppl 1:S10-5. doi: 10.1093/cid/cis361.

abstract

An estimated 2%-3% of the world's population is living with hepatitis C virus (HCV) infection, and each year, >350 000 die of HCV-related conditions, including cirrhosis and liver cancer. The epidemiology and burden of HCV infection varies throughout the world, with country-specific prevalence ranging from <1% to >10%. In contrast to the United States and other developed countries, HCV transmission in developing countries frequently results from exposure to infected blood in healthcare and community settings. Hepatitis C prevention, care, and treatment programs must recognize country-specific epidemiology, which varies by setting and level of economic development. Awareness of the Global epidemiology of HCV infection is important for US healthcare providers treating foreign-born patients from countries where HCV infection is endemic and for counseling patients who travel to these countries. Countries with a high burden of HCV infection also would benefit from establishing comprehensive prevention, care, and treatment programs.



Related Articles
Review Centers for Disease Control and Prevention initiatives to prevent hepatitis C virus infection: a selective update.
Clin Infect Dis. 2012
Review Centers for Disease Control and Prevention initiatives to prevent hepatitis C virus infection: a selective update.
Smith BD, Jorgensen C, Zibbell JE, Beckett GA. Clin Infect Dis. 2012 Jul; 55 Suppl 1:S49-53.
Review Treatment of chronic hepatitis C in Asia: when East meets West.
J Gastroenterol Hepatol. 2009
Review Treatment of chronic hepatitis C in Asia: when East meets West.
Yu ML, Chuang WL. J Gastroenterol Hepatol. 2009 Mar; 24(3):336-45.
Review HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality.
BMC Public Health. 2009
Review HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality.
Mühlberger N, Schwarzer R, Lettmeier B, Sroczynski G, Zeuzem S, Siebert U. BMC Public Health. 2009 Jan 22; 9:34. Epub 2009 Jan 22.
Review Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002.
Clin Liver Dis. 2003
Review Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002.
Seeff LB, Hoofnagle JH. Clin Liver Dis. 2003 Feb; 7(1):261-87.
Projecting severe sequelae of injection-related hepatitis C virus epidemic in the UK. Part 1: Critical hepatitis C and injector data.
J Epidemiol Biostat. 2001
Projecting severe sequelae of injection-related hepatitis C virus epidemic in the UK. Part 1: Critical hepatitis C and injector data.
Bird SM, Goldberg DJ, Hutchinson SJ. J Epidemiol Biostat. 2001; 6(3):243-65; discussion 279-85.
Influence of healthcare-associated factors on the efficacy of hepatitis C therapy.
ScientificWorldJournal. 2012
Influence of healthcare-associated factors on the efficacy of hepatitis C therapy.
Daw MA, Dau AA, Agnan MM. ScientificWorldJournal. 2012; 2012:580216. Epub 2012 Dec 27.

To top Home


Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.